Dr. Frank Mathias

Dr. Frank Mathias joined the Board as Chief Executive Officer in March 2023. Prior to this, Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias was CEO of Medigene AG, a publicly listed immuno-oncology company focusing on the development of T-cell-based cancer therapies. He is currently the Chairman of the Board of Directors of ArcticZymes Technologies ASA, a supplier of best-in-class enzyme technologies.

Over the course of his 30-year career, Dr. Mathias has also served in senior roles at leading global pharmaceutical companies including Amgen Deutschland GmbH, Servier Deutschland GmbH and Hoechst AG, and in 2019, was awarded the title of “EY Entrepreneur of the Year” in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.

Relevant Skills:

• Biotech and Pharma experience
• CDMO Industry experience
• CEO and global leadership
• Manufacturing/Supply Chain